东宝生物 reported revenue of ¥0.41B for the period ended 2026-06-30, +12.4% year on year. Net income was ¥0.04B, a 9.0% net margin on a 22.1% gross margin. The largest revenue line is 胶囊业务 at 50% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.41B | +12.4% |
| Gross profit | ¥0.09B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.04B | +1.2% |
| Gross margin | 22.1% | Net margin 9.0% |
| Revenue Q/Q | +17.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 胶囊业务 | ¥0.21B | 50.0% |
| 明胶系列产品及副产品磷酸氢钙 | ¥0.17B | 42.0% |
| 胶原蛋白业务 | ¥0.03B | 7.4% |
| 有机肥业务 | ¥0.00B | 0.4% |
| 其他(补充) | ¥0.00B | 0.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.32B | 77.9% |
| R&D | ¥0.01B | 2.6% |
| SG&A | ¥0.03B | 8.3% |
| Tax & other | ¥0.00B | 1.0% |
| Item | Amount |
|---|---|
| Total assets | ¥2.63B |
| Total liabilities | ¥0.87B |
| Shareholders' equity | ¥1.75B |
| Equity / assets | 66.8% |
| Operating cash flow | ¥0.03B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | 146% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普 ・ 依米康 ・ 初灵信息 ・ 金信诺
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies